Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

Trial Profile

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2017

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Acronyms TRIPLE
  • Most Recent Events

    • 23 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2018.
    • 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 Sep 2016 Planned number of patients changed from 33 to 53.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top